AI
PCRX icon

Axiom Investors’s Pacira BioSciences PCRX Stock Holding History

Axiom Investors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,691
Closed -$627K – 149
2017
Q3 		$627K Sell
16,691
-19,733
-54% -$794K 0.01% 132
2017
Q2 		$1.74M Buy
36,424
+5,988
+20% +$278K 0.04% 125
2017
Q1 		$1.39M Buy
+30,436
New +$1.32M 0.04% 140
2015
Q1 		– Sell
-17,390
Closed -$1.54M – 156
2014
Q4 		$1.54M Sell
17,390
-8,084
-32% -$765K 0.04% 125
2014
Q3 		$2.47M Sell
25,474
-2,826
-10% -$275K 0.06% 101
2014
Q2 		$2.6M Buy
28,300
+19,770
+232% +$1.51M 0.06% 94
2014
Q1 		$597K Buy
+8,530
New +$580K 0.01% 146

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return